Compare Johnson & Johnson (JNJ) vs Zeta Global Holdings Corp (ZETA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Zeta Global Holdings Corp — how do they compare? Johnson & Johnson trades at $261.2 (market cap $618.09B), while Zeta Global Holdings Corp trades at $33.18 (market cap $8.29B). The key difference: Johnson & Johnson is far larger — about 74.6× Zeta Global Holdings Corp's market cap, and Johnson & Johnson pays a 2.09% dividend while Zeta Global Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Zeta Global Holdings Corp for 19 Days on average.
| JNJ | ZETA | |
|---|---|---|
Market Cap | $618.09B | $8.29B |
Volume | 6,050,983 | 7,156,795 |
Sector | Health | Technology |
52-Week High | $278.43 | $33.74 |
52-Week Low | $186.00 | $14.55 |
Typical Hold Time | 129 Days | 19 Days |
Enterprise Value | $646.37B | $8.18B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
ZETA trades at $33.63, down 0.33% on the day, showing resilience near its 52-week high territory. The stock maintains strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent expansion into the UK market and growing AI platform adoption support the positive sentiment, though negative net income margins and elevated valuation metrics warrant caution.
The outlook remains cautiously optimistic with 75% analyst buy ratings and a $32.40 consensus target. Key opportunities include accelerating revenue growth and AI-driven customer expansion, while risks involve negative profitability, high valuation multiples, and potential insider fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Zeta Global Holdings Corp
Zeta Global is a leading data-driven marketing technology company that provides an omnichannel AI Marketing Cloud. By leveraging a proprietary data cloud of over 2.4 billion deterministic identities, it enables enterprise brands to acquire, grow, and retain customers through predictive intelligence and automated, agentic workflows.
Read more on ZETA →
